GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.
Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk. Patients with T2DM initiating GLP-1 RAs or metformin as first-line monotherapy were included (87,229 matched patients per cohort).
The researchers found that compared with metformin, GLP-1 RA use was associated with a significantly lower risk for overall dementia, Alzheimer disease, and nonvascular dementias (adjusted hazard ratios, 0.90, 0.88, and 0.75, respectively). For vascular dementia, no significant difference was observed. Consistent benefit was seen across age and sex in subgroup analyses, with the strongest effect seen among older adults and women.
"Despite limitations such as residual confounding, the findings remain robust and suggest GLP-1 RAs could redefine T2DM-related dementia prevention strategies, warranting further randomized controlled trials to confirm these results," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Sense of Life Purpose Lowers Risk for Cognitive Impairment
THURSDAY, Sept. 4, 2025 -- A sense of purpose in life (PiL) is associated with a lower risk for and later onset of cognitive impairment, according to a study published online in...
Adults With Learning Disabilities, New Diabetes Have Shorter Time to Insulin Initiation
THURSDAY, Sept. 4, 2025 -- Adults with learning disabilities and newly diagnosed type 2 diabetes (T2D) have better short-term glycemic control, but also faster progression to...
Intake of Low-, No-Calorie Sweeteners Tied to Faster Cognitive Decline
WEDNESDAY, Sept. 3, 2025 -- Consumption of low- and no-calorie sweeteners (LNCSs) is associated with faster cognitive decline, according to a study published online Sept. 3 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.